03:51 PM EDT, 05/28/2025 (MT Newswires) -- Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund (XLV) easing 0.4%.

The iShares Biotechnology ETF (IBB) shed 0.5%.

In corporate news, Ocular Therapeutix ( OCUL ) shares jumped 14% after the company said it will close enrollment this week in its registration trial evaluating Axpaxli for wet age-related macular degeneration.

Candel Therapeutics ( CADL ) shares popped 4.8% after it said Wednesday that the US Food and Drug Administration had granted Regenerative Medicine Advanced Therapy, or RMAT, designation to CAN-2409 to treat prostate cancer.

Boston Scientific ( BSX ) shares dropped 1.5%. The company plans to stop global sales of its Acurate valve systems and halt efforts to get approvals from the US and other markets.

InflaRx ( IFRX ) shares tumbled 60% after the company said it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.

Spero Therapeutics ( SPRO ) shares soared 215% after the company and GSK (GSK) said a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.